Check out this new study using PredicineEPIC™ on day 4 at ASCO2024!

High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.

Learn more: meetings.asco.org/abstracts-pres…

We are thrilled to present five ctDNA studies on day 3 #ASCO24 . These include Predicine's mutation- & methylation-based MRD research utilizing blood and urine samples in breast & bladder cancers, along with an ultra-sensitive ctDNA study for treatment selection in breast cancer.

We are thrilled to present 5 ctDNA studies on day 3 of #ASCO24 . These include Predicine's mutation- & methylation-based MRD research utilizing blood & urine samples in breast and bladder cancers, along with an ultra-sensitive ctDNA study for treatment selection in breast cancer.

Exciting News from Predicine!

Three studies were presented on day 2 of #ASCO24 featuring PredicineCARE™, PredicineSCORE™, and PredicineATLAS™.

We’re so excited to be at #ASCO24 ! Stop by Predicine Booth #14105 to explore our advanced liquid biopsy solutions, centralized lab network, decentralized CDx, NGS kit manufacturing for global clinical trials, biomarker discovery, and CDx development.

Join us at the 2024 ASCO Annual Meeting in Chicago from May 31st to June 3rd!

We are excited to present 10 ctDNA studies at ASCO 2024! Click here to view the 10 studies: lnkd.in/gAZ96HyC

May is Bladder Cancer Awareness Month, a time to raise awareness about a disease that impacts over 1.9m patients globally.

Together, we can make a difference in the fight against bladder cancer. Let's raise awareness, promote early detection, and innovate medicine together!

Join us at the 2024 ASCO Annual Meeting in Chicago from May 31st to June 3rd where we are thrilled to showcase 9 ctDNA studies at ASCO 2024

Read the full press release here: globenewswire.com/news-release/2…

Come meet the team at booth #14105 outlook.office365.com/book/MeetingAS…

On Day 3 of AUA, we are delighted to present two urine-based studies on non-muscle invasive bladder cancer, showcasing the clinical utility of Predicine liquid biopsy solutions for patients prior to repeat transurethral resection of bladder tumors (rTURBT)

Predicine will present two liquid biopsy studies with Moffitt Cancer Center at the American Urological Association 2024 Annual Meeting, highlighting the clinical utility of Predicine liquid biopsy solutions for patients prior to repeat transurethral resection of bladder tumors.

We are pleased to announce the collaboration with #Apollomics on the PredicineCARE™ blood cfDNA NGS assay as a companion diagnostic ( #CDx ) development for non-small cell lung cancer (NSCLC) patients.

globenewswire.com/news-release/2…

Predicine is proud to announce the launch of PredicineCARE™ NGS kit for tumor profiling.

Read more about PredicineCARE™ NGS kit for clinical trial, CDx and patient testing on a global scale: globenewswire.com/news-release/2…

Explore the latest study on PredicineCOMPLETE™ unveiled on day 1 of AACR 2024!

The study delves into integrated analysis of cfDNA fragmentomics, DNA methylation, and cfRNA transcription in metastatic castration-resistant prostate cancer (mCRPC).

Join us at the 2024 AACR annual meeting in San Diego from April 5th to 10th!

We're excited to present 15 groundbreaking ctDNA studies at AACR 2024! predicine.com/2024/04/03/pre…

Visit Predicine Booth #1617 to discover our cutting-edge liquid biopsy solutions!

We are excited to speak & exhibit at the 5th Biomarker & Companion Diagnostics Conference in London from March 7-9.

Dr. Pan Du, CTO of Predicine, will speak on day 1 & unveil how Predicine's liquid biopsy solution may help advance your precision oncology programs.

Predicine is exhibiting at the 13th CNAPS International Symposium on Circulating Nucleic Acids in Plasma and Serum in Austria from March 4th-6th.

Check out Predicine at booth #8 to explore our comprehensive ctDNA and cfRNA liquid biopsy offerings for the cancer care continuum.

Join Predicine at the 8th Annual Liquid Biopsy For Precision Oncology Summit in San Diego from Feb. 28 to March 1st! Our Founder and CEO Shidong Jia will take the stage and reveal our innovative oncology liquid biopsy testing in global clinical trials & CDx development.

Join Predicine at the 2024 Biomarker and Companion Diagnostics Conference in San Diego on Feb. 8-9! Predicine will present and reveal our innovative oncology liquid biopsy testing in global markets, from lab testing to CDx.

Check out this new study! Our PredicineCARE™ cfDNA assay was utilized in a study from Tempest on day 3 of ASCO GU!

A Pharmacodynamics & gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab & TPST-1120 in a phase I clinical trial

Learn more about our poster presentation using PredicineWES+™ in collaboration with Moffitt Cancer Center on Day 2 of ASCO GU!

Differential Mutation Profiles Between Benign and Cancerous Urothelium in Patients with Non-Muscle Invasive Bladder Cancer